.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,287,847

« Back to Dashboard

Claims for Patent: 8,287,847

Title:Ion binding polymers and uses thereof
Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.
Inventor(s): Charmot; Dominique (Campbell, CA), Chang; Han-Ting (Livermore, CA), Liu; Mingjun (Campbell, CA), Klaerner; Gerrit (San Jose, CA)
Assignee: Relypsa, Inc. (Santa Clara, CA)
Application Number:12/055,765
Patent Claims: 1. A method for treating hyperkalemia comprising administering a potassium-binding polymer to an animal subject in need thereof wherein the administration is oral, intestinal, or rectal, the potassium-binding polymer being a crosslinked cation exchange polymer comprising acid groups in their acid or salt form, and the crosslinked cation exchange polymer comprising a crosslinked carboxylic polymer having fluoride attached to the carbon atom alpha to the carboxylic acid group.

2. The method of claim 1 wherein the potassium-binding polymer has a swelling ratio of less than 5.

3. The method of claim 1 wherein the potassium-binding polymer has a swelling ratio of less than 3.

4. The method of claim 1 wherein the subject is a human.

5. The method of claim 1 wherein the pharmaceutical composition is administered in the form of a chewable tablet.

6. The method of claim 4 wherein the potassium-binding polymer is administered in a dose of about 0.5 gram/day to about 30 grams/day.

7. The method of claim 1 wherein the ionization of the acid groups is greater than 75% at the physiological pH in the colon.

8. The method of claim 1 wherein the potassium-binding polymer comprises a Ca.sup.2+cationic counterion.

9. A method for treating hyperkalemia comprising administering a potassium-binding polymer to an animal subject in need thereof wherein the administration is oral, intestinal, or rectal, the potassium-binding polymer being a crosslinked alpha-fluoroacrylic acid polymer.

10. The method of claim 9 wherein the alpha-fluoroacrylic acid polymer is crosslinked with divinyl benzene, ethylene bisacrylamide, N,N'- bis(vinylsulfonylacetyl) ethylene diamine, 1,3-bis(vinylsulfonyl) 2-propanol, vinylsulfone, N,N'- methylenebisacrylamide polyvinyl ether, polyallylether, or a combination thereof.

11. The method of claim 9 wherein the alpha-fluoroacrylic acid polymer is crosslinked with divinyl benzene.

12. The method of claim 9 wherein the subject is a human.

13. The method of claim 12 wherein the potassium-binding polymer is administered in a dose of about 0.5 gram/day to about 30 grams/day.

14. The method of claim 9 wherein the ionization of the acid groups is greater than 75% at the physiological pH in the colon.

15. The method of claim 9 wherein the ionization of the acid groups is greater than 75% at the physiological pH in the colon.

16. The method of claim 9 wherein the potassium-binding polymer is in a bead form.

17. A method for treating hyperkalemia comprising administering a potassium-binding polymer to an animal subject in need thereof wherein the administration is oral, intestinal, or rectal, the potassium-binding polymer being a crosslinked alpha-fluoroacrylic acid polymer comprising a Ca.sup.2+cationic counterion.

18. The method of claim 17 wherein the crosslinked alpha-fluoroacrylic acid polymer has a swelling ratio of less than 3.

19. The method of claim 17 wherein the alpha-fluoroacrylic acid polymer is crosslinked with divinyl benzene, ethylene bisacrylamide, N,N'- bis(vinylsulfonylacetyl) ethylene diamine, 1,3-bis(vinylsulfonyl) 2-propanol, vinylsulfone, N,N'-methylenebisacrylamide polyvinyl ether, polyallylether, or a combination thereof.

20. The method of claim 17 wherein the potassium-binding polymer is in a bead form.

21. The method of claim 17 wherein the subject is a human.

22. The method of claim 21 wherein the potassium-binding polymer is administered in a dose of about 0.5 gram/day to about 30 grams/day.

23. The method of claim 17 wherein the ionization of the acid groups is greater than 75% at the physiological pH in the colon.

24. The method of claim 17 wherein the ionization of the acid groups is greater than 75% at the physiological pH in the colon.

25. The method of claim 17 wherein the potassium-binding polymer is in a bead form.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc